Schreiner MediPharm Reports Needle-Trap Proves More Sustainable than Conventional Needle Safety Systems

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has investigated the comparable sustainability of its Needle-Trap safety solution relative to conventional needle safety systems. To evaluate the label’s sustainability, the pharma-label specialist conducted calculations comparing Needle-Trap with conventional needle safety systems.

Needle-Trap proved particularly environmentally friendly primarily due to its special design. Its plastic trap requires less plastic material than conventional needle safety systems and comprises up to 50 percent regranulated material. In addition, due to the label’s compact design, there is no need to adjust its secondary packaging. As a result, Needle-Trap requires less space during transportation and storage. It also generates less waste, which protects the environment and reduces the environmental footprint.

With sustainability playing an increasingly important role in the healthcare industry, it is incumbent upon manufacturers of all products – especially existing ones – to evaluate and optimize their solutions’ materials from an eco-conscious standpoint.

For the testing, calculations were made for 10 million units of one sort for a 1 ml long syringe, and represent best-case scenarios comparing the Needle-Trap label with typical needle safety systems, minus their included syringes. The results provide convincing data supporting Needle-Trap’s superior sustainability:
• 76 percent less space required in cargo containers
• 76 percent less transportation costs
• 80 – 83 percent less CO2 emissions during transport
• 6.6 – 12.7 tons of metal savings
• 37.6 – 53 tons of plastic savings

Furthermore, Needle-Trap’s needle protection label is delivered on rolls – eliminating the need for an additional blister pack – and the grid material waste from label production is recycled.

Consequently, Needle-Trap is a more eco-conscious solution compared with conventional needle safety systems while combining safety for healthcare professionals with cost efficiency for the pharmaceutical manufacturer.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.